Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, June 2, 2016

Escitalopram Improves Stroke Recovery Beyond 3 Months of Treatment

Is this any different that this earlier research? I bet your doctor has not created a stroke depression protocol, probably doesn't even know this shit. A great stroke leader would make sure relevant research is translated into stroke protocols and pushed out to all stoke doctors and hospitals. But we have NO stroke leadership, your children and grandchildren will still be screwed after their strokes.

Common antidepressant can help stroke patients improve movement and coordination Sept. 2015 

Antidepressants may help people recover from stroke even if they are not depressed Jan. 2013


http://dgnews.docguide.com/escitalopram-improves-stroke-recovery-beyond-3-months-treatment?

By Chris Berrie
COPENHAGEN, Denmark -- May 31, 2016 -- The antidepressant escitalopram significantly improves recovery for patients who have had a stroke, with benefits occurring regardless of stroke subtype or baseline depression, and continuing beyond 3 months of treatment, according to results of an open-label study presented at the 2nd Congress of the European Academy of Neurology (EAN).
“Depression is very frequently the result of a stroke,” stated coauthor Aurel Simion, MD, PhD, Municipal Clinical Hospital, University of Oradea, Oradea, Romania, speaking here on May 30. Several studies have shown benefits for antidepressant treatment after stroke, he added.
Dr. Simion and colleagues randomised patients who had had an ischaemic stroke to receive secondary preventive treatment with placebo (n = 46; mean age, 69.2 years) or with escitalopram 19 mg/day (n = 43; mean age, 66.3 years), for 3 months, with follow-up to 12 months. Analyses included various stroke and depression rating scales examined at end of treatment and at 12 months.
Stroke subtypes were equally balanced in the total patient population: thrombotic (33%), lacunar (31%), and cardioembolic (36%).
The National Institutes of Health stroke Severity scale (NIHSS) scores showed trends and some significance between placebo and escitalopram according to thrombotic, lacunar and cardioembolic stroke at 3 months (4.57 vs 2.80, P = .194; 4.00 vs 2.31, P = .141; 3.65 vs 1.47, P = .048; respectively), with all showing significant benefits for active treatment at 12 months (6.21 vs 1.00, P< .001; 5.53 vs 0.46, P< .0001; 2.71 vs 0.67, P = .029). These results were paralleled in the Barthel Index stroke severity rating.
Results were similar, respectively, for depression indices of Hamilton Depression Scale (HAM-D17) at 3 months between placebo and escitalopram according to thrombotic, lacunar and cardioembolic stroke (13.86 vs 11.53, P = .24; 15.00 vs 9.23, P = .001; 10.88 vs 7.67, P = .021) and at 12 months (16.93 vs 7.00, P< .001; 16.67 vs 6.08, P< .001; 10.76 vs 5.47, P = .003). Results from the Beck Depression Inventory (BDI ) paralleled those results between placebo and escitalopram according to thrombotic, lacunar and cardioembolic stroke at 3 months (15.64 vs 14.07, P = .499; 20.67 vs 12.92, P = .001; 16.24 vs 11.93, P = .025) and 12 months (21.43 vs 7.93, P< .001; 24.60 vs 8.54, P< .001; 16.24 vs 8.40, P = .003).
Similar results were demonstrated for improvements in Activities of Daily Living between placebo and escitalopram according to thrombotic, lacunar and cardioembolic stroke at 3 months (4.00 vs 5.13, P = .021; 3.67 vs 5.00, P = .046; 4.82 vs 5.53, P = .154; respectively) and at 12 months (3.36 vs 5.87, P< .001; 2.73 vs 5.85, P< .001; 4.76 vs 5.87, P = .014).
Finally, the investigators observed reductions in stroke recurrence for active treatment according to thrombotic, lacunar and cardioembolic stroke at 3 months (21.4% vs 6.7%; 26.7% vs 7.7%; 23.5% vs 0.0%) and at 12 months (28.6% vs 0.0%; 53.3% vs 0.0%; 17.6% vs 6.7%).
The researchers acknowledge that the mechanism by which antidepressant therapy achieves these benefits is not yet fully understood, and is, therefore, controversial. Regardless, “it is a good measure to treat these patients with serotonin reuptake inhibitor antidepressants,” Dr Simion concluded.
Baseline clinical characteristics were similar across the placebo and escitalopram arms for overall mean NIHSS scores (8.52 vs 8.56) and for depression indices, including overall mean HAM-D17 scores (12.3 vs 13.5) and BDI scores (15.5 vs 17.9).
[Presentation title: Improved Post-Ischaemic Stroke Recovery Over 1 Year With Escitalopram for 3 Months. Abstract P31030]

No comments:

Post a Comment